Bangladeshi pharmaceuticals industry will face challenges after LDC graduation.
TRIPS waiver end poses dual challenge: legal and technological
Renata PLC, one of the country’s leading pharmaceutical companies, discontinued nearly 30 percent of its product line in the last fiscal year after production costs outpaced selling prices, according to the company’s chief executive officer (CEO).
A proposal has been placed to add 79 new items to the duty-free list.
Foreign participants at the 16th Asia Pharma Expo foresee a bright future for Bangladesh’s pharmaceutical industry, given its continuous product development and expanding global footprint.
The Research and Policy Integration for Development (RAPID) conducted the study
